Introduction: Exacerbations of chronic obstructive pulmonary disease (COPD) can be classified by etiology, but endotype diagnosis usually requires invasive airway sampling. This study evaluates a rapid, non‑invasive gold nanoparticle immunoassay to discriminate endotypes by detecting myeloperoxidase (MPO) and interleukin‑5 (IL‑5) in exhaled air. Methods: A prospective study included 99 stable COPD patients, 77 exacerbated COPD patients and 21 controls. Exacerbated patients underwent blood count, sputum culture, and viral PCR and were classified as eosinophilic (≥100 eosinophils/µL, negative culture and PCR, n=21), bacterial (positive culture, n=17), viral (positive PCR, n=14), or NINO (n=25). Surgical masks were analyzed using immunoassays functionalized with MPO and IL‑5 antibodies. Results: Stable COPD patients showed higher MPO and IL‑5 (MPO:96.8±6.8; IL‑5:60.1±3.6 S) than controls (MPO:72.0±7.5; IL‑5:56.3±15.1 S, p<0.0001). During exacerbation, MPO increased in all endotypes compared to stable COPD (p<0.0001), being highest in the bacterial endotype (171.4±5.1 S), followed by viral (169.8±5.4 S), eosinophilic (142.3±4.4 S), and NINO (136.7±6.3 S). IL‑5 was highest in the eosinophilic endotype (142.3±4.4 S), followed by viral (107.4±1.9 S), bacterial (73.9±1.6 S), and NINO (67.7±3.1 S), with significant differences vs. stable COPD and controls (p<0.0001). Conclusion: Non‑invasive MPO and IL‑5 detection enables accurate COPD exacerbation endotyping, supporting personalized therapy. erj;68/suppl_70/PA3781/F1 F1 F1